KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Share-based Compensation (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Share-based Compensation for 8 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 29.26% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.1 million through Dec 2025, down 37.45% year-over-year, with the annual reading at $49.1 million for FY2025, 37.45% down from the prior year.
  • Share-based Compensation hit $11.2 million in Q4 2025 for Vir Biotechnology, down from $11.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $30.6 million in Q2 2023 to a low of $11.2 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $21.2 million across 5 years, with a median of $23.4 million in 2021.
  • Biggest five-year swings in Share-based Compensation: surged 421.44% in 2021 and later tumbled 43.97% in 2024.
  • Year by year, Share-based Compensation stood at $24.4 million in 2021, then increased by 2.03% to $24.9 million in 2022, then grew by 13.7% to $28.3 million in 2023, then tumbled by 43.97% to $15.8 million in 2024, then decreased by 29.26% to $11.2 million in 2025.
  • Business Quant data shows Share-based Compensation for VIR at $11.2 million in Q4 2025, $11.4 million in Q3 2025, and $12.5 million in Q2 2025.